Inve India ▾

Chandan Healthca share price & results

Chandan Healthca· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

North India-based diagnostics and pharmacy chain running NABL/NABH-accredited pathology and radiology centres across Uttar Pradesh and Uttarakhand, plus company-owned retail pharmacy outlets.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue80.9 ₹ crore+19.1% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin24.2 %+3.8 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit7.9 ₹ crore+27.9% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity17.93 %−7.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-9.62 %+8.5 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable−9.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Not in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 3 judged targets kept · 12 open · verdicts reflect calls analysed to Q1 FY27.

Chandan Healthca management guidance track record on Inve: 15 targets tracked across analysed earnings calls (1 achieved, 2 missed, 12 open).

TargetOriginal wordingSaidLatest callVerdict
Pharmacy EBITDA MarginOver 10% in next 6 months or so
Call transcript, Q2 FY26 · 17 Nov 2025		Q2 FY26Q1 FY27:Company announced the divestment of its entire 53.56% stake in Chandan Pharmacy Limited, strategically exiting the low-margin business to focus on diagnostics. This resolves the issue by eliminating the business unit.
Call transcript, Q1 FY27 · 20 Aug 2026		Achieved
New Labs Capacity100 labs in next 3 years
Call transcript, Q2 FY26 · 17 Nov 2025		Q2 FY26Q1 FY27:The original target of '100 labs' was not mentioned. It has been superseded by more specific and ambitious targets: 8 comprehensive centers and 6+ diagnostic centers this year, plus a 'One District One Lab' program.
Call transcript, Q1 FY27 · 20 Aug 2026		Ghosted
Franchisee Collection PointsMore than 1,000 new franchise collection points
Call transcript, Q2 FY26 · 17 Nov 2025		Q2 FY26Q1 FY27:Due to strong response (102 franchises added in one month), management has drastically accelerated the target to achieve 1,000 franchises within the current financial year (FY27).
Call transcript, Q1 FY27 · 20 Aug 2026		Revised Up

Source: Inve Guidance Tracker for Chandan Healthca · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Chandan Healthca's 15 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 12 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹227.2 −0.31% · −₹0.7

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −32.0% 1Y

₹200₹250₹300₹350Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 17 Nov 2025Q3 FY26 — 16 Feb 2026Q4 FY26 — 1 Jun 2026Q1 FY27 — 20 Aug 2026

1Y: ₹334.15 on 24 Oct 2025 → ₹227.2. High ₹347.2 (19 Nov 2025), low ₹191.05 (15 Sept 2026).

Previous close
₹227.9
Market cap
₹572 Cr
52-week range
₹191.05 – ₹347.2
One year
−28.47%
Price to earnings (TTM to Jun 2026)
21.77×
Return on equity (TTM to Jun 2026)
17.93%

Overview

Symbol
NSE:CHANDAN
Exchange
NSE
Currency
INR

What Chandan Healthca does

Based on the company's own presentations, annual report and earnings calls.

Chandan Healthcare operates a network of diagnostic centres, laboratories and sample-collection points across Uttar Pradesh, Uttarakhand and neighbouring states, offering pathology testing (routine, specialised hormone/tumour-marker/genetic panels and preventive health packages) and radiology imaging (X-ray, ultrasound, CT, MRI, PET and mammography). It complements this with a pharmacy arm running company-owned retail outlets selling pharmaceuticals, surgical products and FMCG items, backed by a centralised cold-chain distribution system. The company serves retail walk-in patients (B2C), institutional tie-ups with private hospitals and clinics (B2B), and government public-private-partnership diagnostic contracts (B2G), with all centres company-owned and operated for consistent quality control.

Segments

  • Pathology
  • Radiology
  • Pharmacy
Diagnostic centres
60+
Geographic presence
51 cities across 13 states
Sample collection centres
360
Team size
1,700+
Total tests conducted (FY26)
8.8 million
Total patient count (FY25)
18.21 lakh
Founded 2003Headquarters Lucknow, Uttar Pradesh, IndiaEmployees 1,700 (Q3 FY26) Company website

How the price took the results

close before → close after

Q1 FY27
−1.8%
20 Aug
Q4 FY26
−6.0%
1 Jun
Q3 FY26
−8.0%
16 Feb
Q2 FY26
+7.6%
17 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Chandan Healthca

Free account: one company. Everything above stays public.

Write why you follow Chandan Healthca and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Chandan Healthca

Guides on how to read this kind of business and the numbers that matter.